InvestorsObserver
Sign Up Login

NVCR NovoCure Limited

$58.24 $-0.79 (-1.34%)
15 Minute Delayed Price Enable Real-Time Price
Add to Watchlist Compare
Overall

NVCR Stock Analysis Overview

What this means: InvestorsObserver gives NovoCure Limited (NVCR) an overall rank of 35, which is below average. NovoCure Limited is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 35 means that 65% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

NVCR Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

NVCR Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

NVCR Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

NVCR Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

NVCR Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

NVCR Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

NVCR Stock Analysis Overview

What this means: InvestorsObserver gives NovoCure Limited (NVCR) an overall rank of 35, which is below average. NovoCure Limited is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 35 means that 65% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full NVCR report

NVCR Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

NVCR Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

NVCR Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

NVCR Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

NVCR Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

NVCR Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

NovoCure Limited (NVCR) Analyst Forecast

NVCR Price, Volume, Earnings, and Dividend Date

  • Last Price $58.24
  • Previous Close $59.03
  • Change $-0.79
  • Open $59.81
  • Volume 420,256
  • Avg. Volume (100-day) 851,012
  • Market Cap 6,141,709,276
  • Days Range 57.69 - 59.9399
  • 52-week Range 56.06 - 120.03
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E 1640
  • EPS —
  • Earnings Date 04/27/23
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Avg. Analyst Rec. Premium
  • Beta 1.904
  • PEG Ratio —

NovoCure Limited (NVCR) Company Description

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.

NovoCure Limited (NVCR) Stock Chart

View Interactive NVCR chart

My Watchlists

Top Stocks in Medical Instruments & Supplies